NSF International Expands Health Sciences Group With Acquisition of Majority Interest in Amarex CRO

The press release below was released by NSF on October 9, 2019. To view the original release, visit: http://www.nsf.org/newsroom/nsf-int-expands-health-science-consulting-services-acquisition-amarex-cro

The transaction creates a single access point for medical device and pharma/biotech product developers seeking integrated, expert services throughout the entire product lifecycle.

ANN ARBOR, Mich. - Global public health organization NSF International has acquired a majority interest in Amarex Clinical Research, LLC, a clinical stage contract research organization (CRO) headquartered in Germantown, Maryland. The transaction supports NSF International’s mission of protecting and improving human health through expanded consulting services to the medical device and pharma/biotech industries. As part of NSF International’s global health science consulting business, the highly-respected CRO will be known as Amarex Clinical Research, LLC, an NSF International company.

Amarex Clinical Research, LLC will gain access to NSF International’s expert network and international scope. As part of NSF’s global network of locations, Amarex will continue to operate from its U.S. office near Washington, D.C. The company also operates an office in Taiwan and has a developing presence in Europe.

“NSF International plays an important role in the pharmaceutical and biotech industry as a champion of quality, scientific rigor and best practices aimed at protecting and improving human health. Together with Amarex, we are creating a single source for integrated, expert health science consulting services across the entire product lifecycle,” said NSF International President and CEO Kevan Lawlor. “Amarex brings clinical trial expertise to NSF International’s large base of training, quality and consulting clients, and Amarex’s CRO clients may now benefit from NSF International’s global reach and expertise in European Union Qualified Person and Medical Device Regulation training, chemistry manufacturing and controls support, and supplement testing inspection and certification.”

“Amarex is excited to join the NSF International family. Amarex will be able to leverage NSF International’s global infrastructure to expand our contract research capabilities and better serve clients with the design and execution of clinical trials and navigating the FDA, TFDA and EMA regulatory approval process,” said Amarex founder Dr. Kazem Kazempour, who will continue as president and CEO of Amarex, an NSF International company. “NSF International’s operational excellence will accelerate our expert team’s leap forward in the CRO market, and better help pharmaceutical, biotech and medical device/diagnostic companies develop products and services that will protect and improve human health while minimizing inefficiencies to save time and reduce unnecessary costs.”

Since 1998, Amarex Clinical Research has been helping biotech, medical device and pharmaceutical companies conduct scientifically sound clinical trials and navigate complex regulatory environments in a wide range of therapeutic indications, including oncology, central nervous system, wound healing, infectious disease, cardiovascular and urology.

As part of NSF International, Amarex will support companies with regulatory affairs, project/trial management, clinical operations, biostatistics, data management, pharmacovigilance, data monitoring committees, medical writing and consulting.

For media inquiries, please contact Thomas Frey at media@nsf.org or +1-734-214-6242.

In 2019, NSF International is celebrating 75 years of protecting and improving human health. The global public health organization facilitates standards development, and tests and certifies products for the food, water, health sciences and consumer goods sectors to minimize adverse health effects and protect the environment. Founded in 1944, NSF is committed to protecting human health and safety worldwide. NSF International is a Pan American Health Organization/World Health Organization (WHO) Collaborating Center on Food Safety, Water Quality and Indoor Environment.

NSF’s health sciences services include training and education, consulting, regulatory guidance, corporate compliance and, separately, auditing, DNA testing, certification and R&D for the pharma biotech, medical device and dietary supplement industries throughout the product lifecycle. NSF facilitated the development of the only American National Standard (NSF/ANSI 173) that verifies the health and safety of dietary supplements and also tests and certifies products to this standard.

Cascade Partners Announced as Finalist in Multiple Categories for the 17th Annual M&A Awards

M A Advisor Award.png

BREAKING NEWS            



SOUTHFIELD, MI, November 5, 2018 The M&A Advisor is pleased to announce finalists of the 17th Annual M&A Advisor Awards. The RECAPITALIZATION OF TCC WIRELESS, LLC for which Cascade Partners served as an advisor was named a finalist in the TELECOMMUNICATIONS SERVICES DEAL OF THE YEAR and DEAL FINANCING OF THE YEAR categories. Additionally, Cascade Partners is a finalist in the BOUTIQUE INVESTMENT BANKING FIRM OF THE YEAR category.

The winners for the M&A Advisor Awards will be announced at the 17th Annual Awards Gala on Tuesday, November 6th at the New York Athletic Club in New York.

“Since the inception of the M&A Advisor Awards in 2002, we have been recognizing the leading dealmakers, firms and transactions. And each year we celebrate the creativity, perseverance and ingenuity of our industry’s professionals”, says David Fergusson, President and Co-Chief Executive Officer of The M&A Advisor. “While our industry has undergone significant transformation since our first awards were presented 16 years ago, we are convinced, more than ever before, that M&A is a driving force of the economy. It is truly an honor for our firm to be able to recognize the contribution that the 2018 award finalists have made.”

According to Gary N. Lewis, Managing Director at Cascade Partners, “This was a hallmark transaction for our capital raising practice and the latest in a series of growth related assignments on which we have supported the TCC Wireless team. We were able to help our client navigate a set of complex dynamics and create an optimal outcome for all parties. We deeply value our numerous long-term, multi-transaction client relationships and take pride in what they reflect about our firm.”

For a detailed list of all of the Award Finalists for the 17th Annual M&A Advisor Awards, please CLICK HERE.

CASCADE PARTNERS is an Investment Banking and Private Investment firm serving entrepreneurs, businesses and investors active in the middle market by providing buy-side acquisition advisory, outsourced corporate development, capital raising and sell-side M&A advisory services. Our team is composed of individuals with experience as operators, investors, executives and advisors who understand all sides of the transaction. We invest in relationships not just transactions and go beyond the deal to create custom solutions for our clients. To learn more, visit www.cascade-partners.com.


The M&A Advisor was founded in 1998 to offer insights and intelligence on M&A activities. Over the past twenty years we have established the premier global network of M&A, Turnaround and Finance professionals. Today, we have the privilege of presenting, recognizing the achievements of, and facilitating connections between the industry’s top performers throughout the world with a comprehensive range of services. To learn more visit www.maadvisor.com.

Media Contact: Heidi Alward, heidia@cascade-partners.com or 248.430.4851